Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474706 | 0.88 | SMN1; SMN2 (0.50) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1934000 | 0.88 | SMN1; SMN2 (0.50) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13192046 | 0.86 | HTR2C (0.56) | HTR2CAGTR2PSEN1PSEN2APH1B | |
| SCHEMBL10169571 | 0.86 | PREP (0.54) | SMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL1190472 | 0.82 | PREP (0.49) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL18428254 | 0.81 | PREP (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19PREP | |
| SCHEMBL2115752 | 0.81 | HTR2C (0.47) | HTR2CAGTR2PSEN1PSEN2APH1B | |
| SCHEMBL2622088 | 0.81 | HTR2C (0.47) | HTR2CAGTR2PSEN1PSEN2APH1B | |
| Hydrochloric Acid SCHEMBL31318026 | 0.81 | AGTR2 (0.44) | HTR2CAGTR2PSEN1PSEN2APH1B | |
| SCHEMBL30587258 | 0.80 | HTR2C (0.51) | HTR2CAGTR2PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | HTR2C 106/4885AGTR2 246/4885PSEN1 939/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | HTR2C 37/4885AGTR2 243/4885PSEN1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.